Mimetica uses a patented chemistry platform technology for creating drug candidates directly from the known structures of natural hormones and peptides. Mimetica’ chemistry platform technology relies on a novel class of mimetic scaffolds or frameworks that mimic an important structural feature of peptide ligands – reverse turns. Reverse turns – beta, gamma and helical – are particularly important structural features of peptide ligands for GPCRs – the single most important receptor class for therapeutics

Sequence information from a native peptide hormone can be transferred to one of Mimetica's proprietary mimetic scaffolds resulting in a small molecule drug mimetic of the native peptide hormone.

Mimetica’s technology has been applied to a wide range of GPCR targets and provides the following advantages:

• rapid and cost effective generation of lead compounds;
• compound novelty; and
• superior optimisation for receptor selectivity.

.